Brand name authorized in: Austria Finland Netherlands
The drug ADPORT contains one active pharmaceutical ingredient (API):
Tacrolimus is a highly potent immunosuppressive agent. In particular, tacrolimus inhibits the formation of cytotoxic lymphocytes, which are mainly responsible for graft rejection. Tacrolimus suppresses T-cell activation and T-helper-cell dependent B-cell proliferation, as well as the formation of lymphokines (such as interleukins-2, -3, and γ-interferon) and the expression of the interleukin-2 receptor.
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
This drug has been assigned below unique identifiers within the countries it is being marketed: